Differential promoter usage by the rat 11 beta-hydroxysteroid dehydrogenase gene
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
11 beta-hydroxysteroid dehydrogenase (11 beta-OHSD) catalyzes the conversion of physiological glucocorticoids to inactive products, thus protecting nonselective renal mineralocorticoid receptors from circulating glucocorticoids (ensuring aldosterone selectivity in vivo) and modulating glucocorticoid access to mineralocorticoid receptors and glucocorticoid receptors in other tissues. Detection of multiple mRNA and immunoreactive 11 beta-OHSD species in kidney, but not liver, extracts suggests the presence of tissue-specific isoforms. To determine whether differential promoter usage might explain the mRNA heterogeneity we cloned and sequenced rat 11 beta-OHSD genomic DNA. Total identity was found between the nucleotide sequence of exons 1 and 2 and the previously published rat liver cDNA. Using both primer extension and RNase protection analyses we found the predominant transcription start site in liver (+1) is 105 base pairs (bp)5' of the start of translation. In kidney two additional Cap sites were detected: 1) 264 bp 5' of exon 1; there is no in-phase open reading frame, suggesting the additional 5' sequence is not translated; and 2) 65 bp upstream of exon 2, within intron A; the predicted truncated protein lacks the first 26 hydrophobic residues. Oligonucleotide probes specific to transcripts arising from each promoter confirmed that all three are employed in kidney, whereas a single predominant species was found in liver, thus demonstrating tissue-specific differential promoter usage of the 11 beta-OHSD gene.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628
Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase
Agarwal, A. K., Monder, C., Eckstein, B., & White, P. C. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47248-7 · Cited by 455
Expression of 11β-hydroxysteroid dehydrogenase using recombinant vaccinia virus
Agarwal, A. K., Tusie-Luna, M.-T., Monder, C., & White, P. C. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-12-1827 · Cited by 155
Cited by
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
“The human cDNA of approximately 1.4 kb in length predicted an open reading frame of 876 bp and a protein of 292 amino acids, which was 77% identical at the amino acid level to the rat enzyme (Fig.”
Influential11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887
11β-Hydroxysteroid Dehydrogenase
Stewart, P. M., & Krozowski, Z. S. (1997) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)60646-9 · Cited by 718
11β-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess*
White, P. C., Mune, T., & Agarwal, A. K. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0288 · Cited by 517
Mensah-Nyagan, A. G., Do-Rego, J.-L., Beaujean, D., Luu-The, V., Pelletier, G., & Vaudry, H. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01395-4 · Cited by 379
Metadata
- Authors
- Moisan, M. P.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1992-07-01
- Volume
- 6
- Issue
- 7
- Pages
- 1082-1087
- ISSN
- 0888-8809 (ISSN-L)
- OpenAlex
- W2152902566
- Cited by
- 51
- References
- 3
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.